Thus, increased interleukin-6 levels in bone marrow of patients with SDS, together with mTOR-STAT3 axis hyper-activation in hematopoietic cells, may clarify the reason why these subjects are prone to develop AML. This evidence concerns the gene IL6 and acute myeloid leukemia.